MEI Pharma and Kyowa Kirin announced results from the ongoing Phase 2 TIDAL study evaluating zandelisib as a single agent for follicular lymphoma (FL) patients…
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and…
Starpharma announced positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel. Data showed high levels of efficacy as…
Tetra Biopharma announced positive initial clinical data from its ongoing Phase 2 clinical trials, REBORN1 and PLENITUDE, evaluating QIXLEEF for severe cancer pain. QIXLEEF is a botanical…
Cancer Research UK reported earlier in the week that an international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center (MSK), New York, and Dana-Farber…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
